NCT07002034 - RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions

Adjustment Disorder

Interventions

DRUG

RE104 for Injection

Single, subcutaneous dose of RE104 for Injection

Trial Locations (12)

10016

RECRUITING

NYU Langone Center for Psychedelic Medicine, New York

20850

RECRUITING

Sunstone Therapies, PC, Rockville

22903

RECRUITING

UVA Center for Psychiatric Clinical Research, Charlottesville

33613

RECRUITING

University of South Florida, Department of Psychiatry and Behavioral Neuroscience, Tampa

35209

RECRUITING

UAB, Psychiatry and Behavioral Neurology, Birmingham

43210

RECRUITING

The Ohio State University, Department of Psychiatry, Columbus

48377

RECRUITING

Henry Ford Health, Novi

84020

RECRUITING

Cedar Clinical Research Inc., Draper

87131

RECRUITING

University of New Mexico, School of Medicine, Albuquerque

92037

RECRUITING

Kadima Neuropsychiatry Institute, San Diego

95403

RECRUITING

Providence Medical Foundation, Santa Rosa

96817

RECRUITING

Hawaii Pacific Neuroscience, Honolulu

All Listed Sponsors

lead

Reunion Neuroscience Inc

INDUSTRY